University of Minnesota built SpudCell from scratch that eats, divides, and evolves

A team at the University of Minnesota just built a cell from scratch that eats, grows, divides, and evolves. They call it SpudCell, and the behavior is not a metaphor. It feeds, it grows, it divides, and it even competes with its own offspring.

Here is the twist that matters: its makers do not claim it is alive. That detail is not a technicality for them. It is the boundary they are drawing, even as the system they created performs core “life-like” functions. In other words, the experiment is forcing everyone watching to ask a practical question: if something does the job of a biological cell, what does “alive” even mean for science, policy, and commercialization?

To understand why this is a big deal, you have to zoom out from the lab bench. For decades, researchers have tried to assemble biological behavior from chemistry. The classic approach is to take biological components and strip them down until you can explain how life works. SpudCell goes the other direction. It is described as being built from scratch, with the goal of showing that cell-like behavior can emerge from designed chemical systems. When the output can feed itself, expand, reproduce, and evolve under competition, the discussion shifts from “cool chemistry” to “functional biology,” regardless of the label.

The “competes with its own offspring” part is especially consequential. Evolution is often discussed as a slow, abstract process. Here, the system’s offspring are not just copies sitting on the side. They are competitors. That implies selection pressure inside the system, and selection pressure is the engine that turns variation into change. Even if researchers avoid calling the thing alive, the functional behavior is closer to Darwin than it is to a passive chemical reaction. That creates a different set of research incentives too. Once a system can reliably reproduce and compete, it becomes a platform for studying how complexity ramps up, which is the kind of capability that attracts funding and accelerates follow-on experiments.

Now add the regulatory and governance angle, because this is where “we are not calling it alive” could either calm the waters or become a loophole people test. Biological organisms and biological materials are often treated differently than chemical entities, especially when it comes to biosafety review and containment expectations. If regulators anchor their decisions on the label “alive,” then a boundary-drawing statement by researchers might delay scrutiny. But if regulators anchor on function, then systems that feed, grow, divide, and evolve will quickly trigger the same risk questions as living systems. The source you provided does not spell out the regulatory pathway for SpudCell. Still, the practical issue for decision-makers is clear: the line regulators draw between chemistry and biology could be pressured by work that performs biological functions while rejecting biological labels.

This also matters to investors and boards because the commercialization playbook for “life-like systems” is being written in real time. Companies in synthetic biology, drug discovery, and materials science all have incentives to chase platforms that can self-replicate or self-adjust, because those traits can reduce manual intervention and potentially improve throughput. SpudCell is not described as a product. But a demonstrated capability like “built from scratch” signals a technical credibility milestone. In markets where first movers often set standards and capture mindshare, platforms that blur traditional categories can become the gravitational center for capital.

Second-order, the “chemistry-biologiy boundary” getting thinner can also reshape how research teams evaluate success. If a system can be engineered to behave like a cell, then the metrics shift. Instead of only tracking molecular outputs, teams track population dynamics: growth rates, division behavior, and competitive outcomes among offspring. That changes the skill sets that get hired, the experiments that get funded, and the way results are validated. It can also change how universities and labs communicate with the public, because the phrase “built a cell from scratch” triggers an immediate intuition in non-specialists. The researchers’ refusal to call it alive is a communications strategy and a scientific disclaimer at the same time.

Strategically, peers in adjacent fields should take the signal seriously. SpudCell shows that core cell functions can be assembled in a way that behaves like a self-sustaining, competing population, even when scientists insist it is not alive. If you lead an innovation portfolio, sit on a board overseeing biosafety governance, or invest in platform technology, the takeaway is not to argue about labels. The takeaway is to plan for systems whose behavior looks biological. Those systems will force new answers about oversight, safety, and what kinds of capabilities you are effectively underwriting when you fund the next generation of “from scratch” biological engineering.